Skip to main content

Pancreatic Cancer Awareness Month

New Content Item

Explore our retrospective article collection from across our open access titles for Pancreatic Cancer Awareness Month, featuring vital information on risk factors, early detection methods, treatment options, and the latest research breakthroughs, dedicated to fostering understanding, support, and hope in the fight against pancreatic cancer.

The following journals are participating in this retrospective collection: Journal of Hematology & Oncology, Molecular Cancer, Journal of Experimental and Clinical Cancer Research, Cancer & Metabolism, Biomarker Research, Cancer Cell International, Cancer Imaging and Radiation Oncology

  1. Pancreatitis is known to be an important risk factor for pancreatic ductal adenocarcinoma (PDAC). However, the exact molecular mechanisms of how inflammation promotes PDAC are still not fully understood. Regna...

    Authors: Junya Okabe, Takahiro Kodama, Yu Sato, Satoshi Shigeno, Takayuki Matsumae, Kazuma Daiku, Katsuhiko Sato, Teppei Yoshioka, Minoru Shigekawa, Masaya Higashiguchi, Shogo Kobayashi, Hayato Hikita, Tomohide Tatsumi, Toru Okamoto, Takashi Satoh, Hidetoshi Eguchi…
    Citation: Journal of Experimental & Clinical Cancer Research 2023 42:262
    Content type: Research Published on:

  2. Pancreatic cancer is one of the most challenging cancers due to its high mortality rates. Considering the late diagnosis and the limited survival benefit with current treatment options, it becomes imperative t...

    Authors: María Victoria García-Ortiz, Pablo Cano-Ramírez, Marta Toledano-Fonseca, Enrique Aranda and Antonio Rodríguez-Ariza
    Citation: Biomarker Research 2023 11:88
    Content type: Review Published on:

  3. This study aimed to investigate the ability of Al18F-NOTA-FAPI PET/CT to diagnose pancreatic carcinoma and tumor-associated inflammation with the comparison of 18F-FDG PET/CT.

    Authors: Zhehao Lyu, Wei Han, Qi Zhang, Hongyue Zhao, Shan Liu, Yan Wang, Jin He, Changjiu Zhao, Lin Tian and Peng Fu
    Citation: Cancer Imaging 2023 23:86
    Content type: Research article Published on:

  4. Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure of standard therapy (NCT0458147...

    Authors: Changsong Qi, Tong Xie, Jun Zhou, Xicheng Wang, Jifang Gong, Xiaotian Zhang, Jian Li, Jiajia Yuan, Chang Liu and Lin Shen
    Citation: Journal of Hematology & Oncology 2023 16:102
    Content type: Correspondence Published on:

  5. The receptor tyrosine kinases TAM family (TYRO3, AXL, and MERTK) are highly expressed in multiple forms of cancer cells and tumor-associated macrophages and promote the development of cancers including pancrea...

    Authors: Jiawei Fan, Ye Yu, Lanzhen Yan, Yuncang Yuan, Bin Sun, Dong Yang, Nan Liu, Jing Guo, Jie Zhang and Xudong Zhao
    Citation: Journal of Hematology & Oncology 2023 16:77
    Content type: Research Published on:

  6. Pancreatic ductal carcinoma patients have a really poor prognosis given its difficult early detection and the lack of early symptoms. Digital pathology is routinely used by pathologists to diagnose the disease...

    Authors: Francisco Carrillo-Perez, Francisco M. Ortuno, Alejandro Börjesson, Ignacio Rojas and Luis Javier Herrera
    Citation: Cancer Imaging 2023 23:66
    Content type: Research article Published on:

    The Correction to this article has been published in Cancer Imaging 2023 23:111

  7. CT prediction of resectability and prognosis following neoadjuvant treatment (NAT) in patients with pancreatic ductal adenocarcinoma (PDAC) remains challenging. This study aims to determine whether addition of 18

    Authors: Jeongin Yoo, Jeong Min Lee, Ijin Joo, Dong Ho Lee, Jeong Hee Yoon, Mi Hye Yu, Jin-Young Jang and Sang Hyub Lee
    Citation: Cancer Imaging 2023 23:49
    Content type: Research article Published on:

  8. Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Thus, there is an urgent need for safe and effective novel therapies. PDAC’s excessive reliance on glucose metabolism for its metabolic needs pro...

    Authors: Lauren K. Park, Kian-Huat Lim, Jonas Volkman, Mina Abdiannia, Hannah Johnston, Zack Nigogosyan, Marilyn J. Siegel, Janet B. McGill, Alexis M. McKee, Maamoun Salam, Rong M. Zhang, Da Ma, Karteek Popuri, Vincent Tze Yang Chow, Mirza Faisal Beg, William G. Hawkins…
    Citation: Cancer & Metabolism 2023 11:6
    Content type: Research Published on:

  9. The worldwide increase of pancreatic ductal adenocarcinoma (PDAC), which still has one of the lowest survival rates, requires novel imaging tools to improve early detection and to refine diagnosis. Therefore, ...

    Authors: Diana Pinkert-Leetsch, Jasper Frohn, Philipp Ströbel, Frauke Alves, Tim Salditt and Jeannine Missbach-Guentner
    Citation: Cancer Imaging 2023 23:43
    Content type: Research article Published on:

  10. The advent of next-generation computed tomography (CT)- and magnetic resonance imaging (MRI) opened many new perspectives in the evaluation of tumor characteristics. An increasing body of evidence suggests the...

    Authors: Vitali Koch, Nils Weitzer, Daniel Pinto Dos Santos, Leon D. Gruenewald, Scherwin Mahmoudi, Simon S. Martin, Katrin Eichler, Simon Bernatz, Tatjana Gruber-Rouh, Christian Booz, Renate M. Hammerstingl, Teodora Biciusca, Nicolas Rosbach, Aynur Gökduman, Tommaso D’Angelo, Fabian Finkelmeier…
    Citation: Cancer Imaging 2023 23:38
    Content type: Research article Published on:

  11. The prognosis of pancreatic ductal adenocarcinoma (PDAC) is one of the most dismal of all cancers and the median survival of PDAC patients is only 6–8 months after diagnosis. While decades of research effort h...

    Authors: Yi Han, Pascal Drobisch, Alexander Krüger, Doreen William, Konrad Grützmann, Lukas Böthig, Heike Polster, Lena Seifert, Adrian M. Seifert, Marius Distler, Mathieu Pecqueux, Carina Riediger, Verena Plodeck, Heiner Nebelung, Georg F. Weber, Christian Pilarsky…
    Citation: Journal of Hematology & Oncology 2023 16:7
    Content type: Research Published on:

  12. Profound resistance to chemotherapy remains a major challenge in achieving better clinical outcomes for patients with pancreatic ductal adenocarcinoma (PDAC). Recent studies indicate that gemcitabine (GEM) res...

    Authors: Manoj Amrutkar, Kjersti Berg, Aina Balto, Miguel G. Skilbrei, Anette V. Finstadsveen, Monica Aasrum, Ivar P. Gladhaug and Caroline S. Verbeke
    Citation: Cancer Cell International 2023 23:9
    Content type: Research Published on:

  14. Pancreatic ductal adenocarcinoma (PDAC) lacks effective treatment options beyond chemotherapy. Although molecular subtypes such as classical and QM (quasi-mesenchymal)/basal-like with transcriptome-based disti...

    Authors: Irina Heid, Corinna Münch, Sinan Karakaya, Smiths S. Lueong, Alina M. Winkelkotte, Sven T. Liffers, Laura Godfrey, Phyllis F. Y. Cheung, Konstantinos Savvatakis, Geoffrey J. Topping, Florian Englert, Lukas Kritzner, Martin Grashei, Andrea Tannapfel, Richard Viebahn, Heiner Wolters…
    Citation: Cancer & Metabolism 2022 10:24
    Content type: Research Published on:

  15. Long non-coding RNA (lncRNA) LINC00460 is an onco-lncRNA in a variety of cancers, including pancreatic cancer (PC). This study is aimed to investigate the regulatory mechanisms of LINC00460 in PC.

    Authors: Jun Yao, Ruoyu Gao, Minghan Luo, Defeng Li, Liliangzi Guo, Zichao Yu, Feng Xiong, Cheng Wei, Benhua Wu, Zhenglei Xu, Dingguo Zhang, Jianyao Wang and Lisheng Wang
    Citation: Cancer Cell International 2022 22:390
    Content type: Primary research Published on:

  16. Localized pancreatic adenocarcinoma carries a poor prognosis even after aggressive therapy. Up to 40% of patients may develop locoregional disease as the first site of failure. As such, there may be a role for...

    Authors: Abhinav V. Reddy, Colin S. Hill, Lei Zheng, Jin He and Amol K. Narang
    Citation: Radiation Oncology 2022 17:173
    Content type: Study Protocol Published on:

  17. Tumor-initiating cells (TIC), also known as cancer stem cells, are considered a specific subpopulation of cells necessary for cancer initiation and metastasis; however, the mechanisms by which they acquire met...

    Authors: Donatella Delle Cave, Silvia Buonaiuto, Bruno Sainz Jr, Marco Fantuz, Maria Mangini, Alessandro Carrer, Annalisa Di Domenico, Tea Teresa Iavazzo, Gennaro Andolfi, Carme Cortina, Marta Sevillano, Christopher Heeschen, Vincenza Colonna, Marco Corona, Antonio Cucciardi, Martina Di Guida…
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:315
    Content type: Research Published on:

  18. Cancer-associated fibroblasts (CAFs) are considered to play a fundamental role in pancreatic ductal adenocarcinoma (PDAC) progression and chemoresistance. Patient-derived organoids have demonstrated great pote...

    Authors: Sebastian Schuth, Solange Le Blanc, Teresa G. Krieger, Julia Jabs, Miriam Schenk, Nathalia A. Giese, Markus W. Büchler, Roland Eils, Christian Conrad and Oliver Strobel
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:312
    Content type: Research Published on:

  19. Online adaptive stereotactic radiotherapy allows for improved target and organ at risk (OAR) delineation and inter-fraction motion management via daily adaptive planning. The use of adaptive SBRT for the treat...

    Authors: Minsol Kim, Joshua P. Schiff, Alex Price, Eric Laugeman, Pamela P. Samson, Hyun Kim, Shahed N. Badiyan and Lauren E. Henke
    Citation: Radiation Oncology 2022 17:157
    Content type: Case Report Published on:

  20. circRNA has been established to play a pivotal role in tumorigenesis development in a variety of cancers; nevertheless, the biological functions and molecular mechanisms of hypoxia-induced exosomal circRNAs in...

    Authors: Jiewei Lin, Xinjing Wang, Shuyu Zhai, Minmin Shi, Chenghong Peng, Xiaxing Deng, Da Fu, Jiancheng Wang and Baiyong Shen
    Citation: Journal of Hematology & Oncology 2022 15:128
    Content type: Research Published on:

  21. Pancreatic cancer is the most lethal type of malignancy and is characterized by high invasiveness without severe symptoms. It is difficult to detect PC at an early stage because of the low diagnostic accuracy ...

    Authors: Haotian Wu, Suwen Ou, Hongli Zhang, Rui Huang, Shan Yu, Ming Zhao and Sheng Tai
    Citation: Cancer Cell International 2022 22:220
    Content type: Review Published on:

  22. Undifferentiated carcinoma with osteoclast-like giant cells (OGCs) of pancreas (UCOGCP) is a rare subtype of pancreatic ductal adenocarcinoma (PDAC), which had poorly described histopathological and clinical f...

    Authors: Xinbo Wang, Jiaying Miao, Sizhen Wang, Rongxi Shen, Shuo Zhang, Yurao Tian, Min Li, Daojun Zhu, Anlong Yao, Wei Bao, Qun Zhang, Xingming Tang, Xingyun Wang and Jieshou Li
    Citation: Molecular Cancer 2022 21:133
    Content type: Research Published on:

  23. Up to 30% of pancreatic cancer patients initially present locally advanced (LAPC). Stereotactic body radiation therapy (SBRT) may be an additional palliative treatment option when curative resection is no long...

    Authors: Marlies Vornhülz, Sofia Anton, Balint Eross, Zsolt Szakács, Peter Hegyi, Ivonne Regel, Claus Belka, Maximilian Niyazi, Julia Mayerle and Georg Beyer
    Citation: Radiation Oncology 2022 17:108
    Content type: Review Published on:

  24. Ubiquitination is a basic post-translational modification of intracellular proteins and can be reversed enzymatically by DUBs (deubiquitinating enzymes). More than 90 DUBs have been identified. Among them, the...

    Authors: Zhishuo Zhang, Wenxia Zhao, Yiming Li, Yang Li, Hanzeng Cheng, Liyun Zheng, Xiaoyu Sun, Hao Liu and Rongguang Shao
    Citation: Cancer Cell International 2022 22:203
    Content type: Primary research Published on:

  25. Advanced pancreatic ductal adenocarcinoma (PDAC) is usually an incurable malignancy that needs newer therapeutic targets. Interleukin-1 receptor accessory protein (IL1RAP) is an innate immune mediator that reg...

    Authors: Yang Zhang, Xiaoyi Chen, Huamin Wang, Shanisha Gordon-Mitchell, Srabani Sahu, Tushar D. Bhagat, Gaurav Choudhary, Srinivas Aluri, Kith Pradhan, Plabani Sahu, Milagros Carbajal, Hui Zhang, Beamon Agarwal, Aditi Shastri, Robert Martell, Daniel Starczynowski…
    Citation: Journal of Hematology & Oncology 2022 15:70
    Content type: Letter to the Editor Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:100

  26. Glycolysis is a pivotal process in metabolic reprogramming of tumorigenesis. Previous research has indicated that lncRNAs might play crucial roles in glycolysis of various tumors. However, the function of lncR...

    Authors: Yuhang Hu, Jiang Tang, Fengyu Xu, Jinhuang Chen, Zhu Zeng, Shengbo Han, Fan Wang, Decai Wang, Mengqi Huang, Yong Zhao, Yan Huang, Wenfeng Zhuo and Gang Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:69
    Content type: Research Published on:

  27. Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy (GPT) for non-metastatic, locally advanced pancreatic cancer (LAPC) remain unclear. This study aimed to determine the fa...

    Authors: Yuta Ogura, Kazuki Terashima, Yoshihide Nanno, SungChul Park, Masaki Suga, Daiki Takahashi, Yoshiro Matsuo, Nor Shazrina Sulaiman, Sunao Tokumaru, Tomoaki Okimoto, Hirochika Toyama and Takumi Fukumoto
    Citation: Radiation Oncology 2022 17:32
    Content type: Research Published on:

  28. Mortality associated with pancreatic cancer is among the highest of all malignancies, with a 5-year overall survival of 5–10%. Immunotherapy, represented by the blocking antibodies against programmed cell deat...

    Authors: Lingyue Liu, Xing Huang, Fukang Shi, Jinyuan Song, Chengxiang Guo, Jiaqi Yang, Tingbo Liang and Xueli Bai
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:56
    Content type: Review Published on:

  29. Pain symptoms in the upper abdomen and back are prevalent in 80% of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), where the current standard treatment is a systemic therapy consisting of a...

    Authors: M. Pavic, M. Niyazi, L. Wilke, S. Corradini, M. Vornhülz, U. Mansmann, A. Al Tawil, R. Fritsch, J. Hörner-Rieber, J. Debus, M. Guckenberger, C. Belka, J. Mayerle and G. Beyer
    Citation: Radiation Oncology 2022 17:18
    Content type: Study protocol Published on:

  30. Cancer-associated fibroblasts (CAFs) are critically involved in gemcitabine (GEM) resistance in pancreatic ductal adenocarcinoma (PDAC). However, the underlying mechanism by which CAFs promote chemotherapy res...

    Authors: Chonghui Hu, Renpeng Xia, Xiang Zhang, Tingting Li, Yuancheng Ye, Guolin Li, Rihua He, Zhihua Li, Qing Lin, Shangyou Zheng and Rufu Chen
    Citation: Molecular Cancer 2022 21:24
    Content type: Research Published on:

  31. Molecular markers play an important role in predicting clinical outcomes in pancreatic adenocarcinoma (PAAD) patients. Analysis of the ferroptosis-related genes may provide novel potential targets for the prog...

    Authors: Jihua Yang, XiaoHong Wei, Fang Hu, Wei Dong and Liao Sun
    Citation: Cancer Cell International 2022 22:21
    Content type: Primary research Published on:

  32. Circular RNAs (circRNAs) play important roles in many biological processes. However, the detailed mechanism underlying the critical roles of circRNAs in cancer remains largely unexplored. We aim to explore the...

    Authors: Chi Hin Wong, Ut Kei Lou, Frederic Khe-Cheong Fung, Joanna H. M. Tong, Chang-hua Zhang, Ka-Fai To, Stephen Lam Chan and Yangchao Chen
    Citation: Molecular Cancer 2022 21:10
    Content type: Research Published on: